Advertisement
Advertisement

CLDX

CLDX logo

Celldex Therapeutics, Inc

41.71
USD
Sponsored
+0.15
+0.36%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

41.77

+0.05
+0.13%

Celldex Therapeutics, Inc Profile

About

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

Info & Links

CEO

Anthony S. Marucci

Headquarters

53 FRONTAGE ROAD, SUITE 220
HAMPTON, NJ 08827, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.celldex.com

Auditor

PricewaterhouseCoopers LLP

Share holders

120

Employees

198

Celldex Therapeutics, Inc Statistics

Valuation Measures

Market Capitalization2

3.28B

Enterprise Value

3.23B

Enterprise Value/EBITDA(ttm)

-9.89

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

563.31

Price to Book(mrq)

7.15

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

75.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-231608.82%

Return on Equity(ttm)

-57.00%

Return on Invested Capital(ttm)

-54.16%

Return on Assets(ttm)

-51.74%

Income Statement

Revenue(ttm)

157.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

157.00K

EBITDA(ttm)3

-326.66M

Net Income Available to Common(ttm)

-300.55M

Diluted EPS(ttm)

-4.35

Share Statistics

Beta (5Y Monthly)

0.87

52-Week Change

96.65%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

78.53M

Dividend Yield

0.00%

Float4

74.41M

% Held by Insiders

5.20%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

717.59M

Total Cash Per Share(mrq)

9.14

Total Debt(mrq)

1.23M

Total Debt/Equity(mrq)

0.17%

Current Ratio(mrq)

11.82%

Quick Ratio(mrq)

8.92%

Book Value Per Share(mrq)

9.10

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.58

Free Cash Flow(ytd)

-127.82M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement